cd5 antigens

Summary

Summary: Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)

Top Publications

  1. Hawiger D, Masilamani R, Bettelli E, Kuchroo V, Nussenzweig M. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity. 2004;20:695-705 pubmed
    ..The mechanism that mediates this dynamic antigen-specific T cell unresponsiveness differs from previously described forms of tolerance in that it requires that DCs induce CD5 expression on activated T cells. ..
  2. Brossard C, Semichon M, Trautmann A, Bismuth G. CD5 inhibits signaling at the immunological synapse without impairing its formation. J Immunol. 2003;170:4623-9 pubmed
    ..Thus, CD5 is rapidly recruited at the IS and lowers the T cell response elicited by Ag presentation by targeting downstream signaling events without affecting IS formation. ..
  3. Kassiotis G, Zamoyska R, Stockinger B. Involvement of avidity for major histocompatibility complex in homeostasis of naive and memory T cells. J Exp Med. 2003;197:1007-16 pubmed
    ..In contrast to naive T cells, however, memory T cells can reach a homeostatic equilibrium, in which survival/self-renewal of each clone is dissociated from their avidity for MHC-derived signals. ..
  4. Stievano L, Tosello V, Marcato N, Rosato A, Sebelin A, Chieco Bianchi L, et al. CD8+ alpha beta+ T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes. J Immunol. 2003;171:4528-38 pubmed
    ..In addition, they point to the CD3(+)CD8(+)CD5(-) population as a particular T cell subset within the CD8(+) compartment, whose functional properties deserve further attention. ..
  5. Stamou P, de Jersey J, Carmignac D, Mamalaki C, Kioussis D, Stockinger B. Chronic exposure to low levels of antigen in the periphery causes reversible functional impairment correlating with changes in CD5 levels in monoclonal CD8 T cells. J Immunol. 2003;171:1278-84 pubmed
    ..This suggests that up-regulation of negative T cell regulators in peripheral T cells exposed to chronic stimulation by Ag may prevent full functionality and thus avoid overt autoreactivity. ..
  6. Amel Kashipaz M, Huggins M, Lanyon P, Robins A, Powell R, Todd I. Assessment of Be1 and Be2 cells in systemic lupus erythematosus indicates elevated interleukin-10 producing CD5+ B cells. Lupus. 2003;12:356-63 pubmed
    ..Moreover, the cross regulation of IL-10 and IL-6 is disrupted in SLE patients. ..
  7. Cro L, Guffanti A, Colombi M, Cesana B, Grimoldi M, Patriarca C, et al. Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias. Leukemia. 2003;17:125-32 pubmed
    ..0008) and platelet count (cut-off 140 x 10(9)/l; P = 0.0034). Besides recognising the two well-known situations of classic B-CLL and MCL, our IC identified situations with distinct prognostic and/or clinical behaviors. ..
  8. Kobayashi T, Yamaguchi M, Kim S, Morikawa J, Ogawa S, Ueno S, et al. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. Cancer Res. 2003;63:60-6 pubmed
    ..Those results suggest that CD5(+) and CD5(-) DLBCLs have different gene expression signatures in both tumor cells and their vascular systems. ..
  9. Katzenberger T, Lohr A, Schwarz S, Dreyling M, Schoof J, Nickenig C, et al. Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. Blood. 2003;101:699-702 pubmed
    ..On the basis of these findings, CD5(+) DLBLs are likely to arise from the same progenitor cell as the mutated variant of CD5(+) lymphocytic lymphoma/B-cell chronic lymphocytic leukemia (B-CLL). ..

More Information

Publications62

  1. Van de Velde H, von Hoegen I, Luo W, Parnes J, Thielemans K. The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature. 1991;351:662-5 pubmed
    ..The results demonstrate that the B-cell surface protein CD72 (Lyb-2 in mice) is the ligand for CD5. ..
  2. Lundy S, Boros D. Fas ligand-expressing B-1a lymphocytes mediate CD4(+)-T-cell apoptosis during schistosomal infection: induction by interleukin 4 (IL-4) and IL-10. Infect Immun. 2002;70:812-9 pubmed
  3. Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99:815-21 pubmed
    ..Of particular interest is that CD5+ DLBCL was characterized by a survival curve significantly inferior to that for patients with CD5- DLBCL (P =.0026). These findings suggest that CD5+ DLBCL may constitute a unique subgroup of DLBCL. ..
  4. Hippen K, Tze L, Behrens T. CD5 maintains tolerance in anergic B cells. J Exp Med. 2000;191:883-90 pubmed
    ..These data support the hypothesis that CD5 negatively regulates Ig receptor signaling in anergic B cells and functions to inhibit autoimmune B cell responses. ..
  5. Pena Rossi C, Zuckerman L, Strong J, Kwan J, Ferris W, Chan S, et al. Negative regulation of CD4 lineage development and responses by CD5. J Immunol. 1999;163:6494-501 pubmed
    ..Taken together, the data support a general role for CD5 as a negative regulator of Ag receptor signaling in the development and immune responses of CD4 lineage T cells. ..
  6. Bikah G, Carey J, Ciallella J, Tarakhovsky A, Bondada S. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science. 1996;274:1906-9 pubmed
    ..In wild-type B-1 cells, prevention of association between CD5 and mIgM rescued their growth response to mIgM crosslinking. Thus the B cell receptor-mediated signaling is negatively regulated by CD5 in normal B-1 cells. ..
  7. Tarakhovsky A, Muller W, Rajewsky K. Lymphocyte populations and immune responses in CD5-deficient mice. Eur J Immunol. 1994;24:1678-84 pubmed
    ..The mutant mice are able to mount effective immune responses to T cell-dependent and -independent antigens. ..
  8. Kanehira K, Braylan R, Lauwers G. Early phase of intestinal mantle cell lymphoma: a report of two cases associated with advanced colonic adenocarcinoma. Mod Pathol. 2001;14:811-7 pubmed
    ..In both cases, immunohistochemistry (CD20+, CD5+, cyclin D1+, CD10-, and CD23-), and demonstration of clonal immunoglobulin heavy chain and bcl-1 gene rearrangements by PCR analysis confirmed the diagnosis of mantle cell lymphoma. ..
  9. Shores E, Huang K, Tran T, Lee E, Grinberg A, Love P. Role of TCR zeta chain in T cell development and selection. Science. 1994;266:1047-50 pubmed
  10. Tarakhovsky A, Kanner S, Hombach J, Ledbetter J, Muller W, Killeen N, et al. A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science. 1995;269:535-7 pubmed
    ..These observations indicate that CD5 can influence the fate of developing thymocytes by acting as a negative regulator of TCR-mediated signal transduction. ..
  11. Izon D, Punt J, Xu L, Karnell F, Allman D, Myung P, et al. Notch1 regulates maturation of CD4+ and CD8+ thymocytes by modulating TCR signal strength. Immunity. 2001;14:253-64 pubmed
  12. Wong P, Barton G, Forbush K, Rudensky A. Dynamic tuning of T cell reactivity by self-peptide-major histocompatibility complex ligands. J Exp Med. 2001;193:1179-87 pubmed
    ..Our results suggest that the endogenous peptide repertoire modulates T cell responsiveness in the thymus in order to enforce tolerance to self-antigens. ..
  13. Biancone L, Bowen M, Lim A, Aruffo A, Andres G, Stamenkovic I. Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes. J Exp Med. 1996;184:811-9 pubmed
    ..Injection of CD5Rg was found to abrogate development of the disease. Taken together, our results help identify a novel ligand of CD5 and propose a role for CD5 in the regulation of immune responses. ..
  14. Gary Gouy H, Lang V, Sarun S, Boumsell L, Bismuth G. In vivo association of CD5 with tyrosine-phosphorylated ZAP-70 and p21 phospho-zeta molecules in human CD3+ thymocytes. J Immunol. 1997;159:3739-47 pubmed
    ..We conclude that CD5 may affect in vivo the signaling capacity of TCRs expressed by human thymocytes by altering the phosphorylation state of CD3 and/or by retaining ZAP-70 with the p21 species of zeta. ..
  15. Yamaguchi M, Ohno T, Oka K, Taniguchi M, Ito M, Kita K, et al. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol. 1999;105:1133-9 pubmed
    ..These findings suggest that de novo CD5-positive DLBL forms a distinct subgroup of DLBL. ..
  16. Hayakawa K, Asano M, Shinton S, Gui M, Allman D, Stewart C, et al. Positive selection of natural autoreactive B cells. Science. 1999;285:113-6 pubmed
    ..Thus, B cells can be subject to positive selection, generated, and maintained on the basis of their autoreactivity. ..
  17. Smith K, Seddon B, Purbhoo M, Zamoyska R, Fisher A, Merkenschlager M. Sensory adaptation in naive peripheral CD4 T cells. J Exp Med. 2001;194:1253-61 pubmed
    ..Adaptation to peripheral pMHC contact may be important for regulating naive CD4 T cell responsiveness. ..
  18. Love P, Shores E, Johnson M, Tremblay M, Lee E, Grinberg A, et al. T cell development in mice that lack the zeta chain of the T cell antigen receptor complex. Science. 1993;261:918-21 pubmed
    ..Thus, zeta chain expression influences thymocyte differentiation but is not absolutely required for the generation of single positive T cells. ..
  19. Azzam H, Grinberg A, Lui K, Shen H, Shores E, Love P. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J Exp Med. 1998;188:2301-11 pubmed
    ..Taken together, these observations suggest that the developmental regulation of CD5 in response to TCR signaling and TCR avidity represents a mechanism for fine tuning of the TCR signaling response. ..
  20. Perez Villar J, Whitney G, Bowen M, Hewgill D, Aruffo A, Kanner S. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol. 1999;19:2903-12 pubmed
    ..These results suggest a critical role of the CD5 ITIM-like motif, which by binding to SHP-1 mediates the down-regulatory activity of this receptor. ..
  21. Azzam H, DeJarnette J, Huang K, Emmons R, Park C, Sommers C, et al. Fine tuning of TCR signaling by CD5. J Immunol. 2001;166:5464-72 pubmed
    ..Together, these results indicate that inducible regulation of CD5 surface expression during thymocyte selection functions to fine tune the TCR signaling response. ..
  22. Santoni G, Boccanera M, Adriani D, Lucciarini R, Amantini C, Morrone S, et al. Immune cell-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4(+) T cells and possible participation of other local lymphocyte effectors. Infect Immun. 2002;70:4791-7 pubmed
    ..These results strongly suggest that distinct vaginal lymphocyte subsets participate in the adaptive anti-Candida immunity at the vaginal level, with the vaginal CD4(+) T cells probably playing a major role. ..
  23. Carulli G, Stacchini A, Marini A, Ciriello M, Zucca A, Cannizzo E, et al. Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: a multicenter study of 951 bone marrow samples with lymphomatous infiltration. Am J Clin Pathol. 2009;132:186-90; quiz 306 pubmed publisher
    ..There was a 1.89% overall frequency of CD8 coexpression in which B-CLL/SLL had a higher frequency (3.03%) than did the other B-cell neoplasms (1.18%). Most cases were characterized by a favorable outcome...
  24. Corcione A, Arduino N, Ferretti E, Raffaghello L, Roncella S, Rossi D, et al. CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clin Cancer Res. 2004;10:964-71 pubmed
    ..CCR7 and CXCR4 ligands may play a key role in tumor cell migration and spreading in vivo. CXCL12 may additionally contribute by sensitizing MCL B cells to respond to the ligands of other chemokine receptors. ..
  25. Abbasi F, Longo N, Lipsky P, Raveche E, Schleinitz T, Stetler Stevenson M, et al. B-cell repertoire and clonal analysis in unaffected first degree relatives in familial chronic lymphocytic leukaemia kindred. Br J Haematol. 2007;139:820-3 pubmed
    ..Three of these individuals all showed evidence of hyper-somatic mutations. The B-cell repertoire in unaffected FDR in familial CLL offers a new area to investigate the interface between the immune system and lymphoid neoplasm. ..
  26. Xu Z, Butfiloski E, Sobel E, Morel L. Mechanisms of peritoneal B-1a cells accumulation induced by murine lupus susceptibility locus Sle2. J Immunol. 2004;173:6050-8 pubmed
    ..Rag2(-/-) mice. This suggests that peritoneal B-1a cells are replenished throughout the animal life span in B6.Sle2 mice. These results show that Sle2 regulates the size of the B-1a cell compartment at multiple developmental checkpoints. ..
  27. Koide N, Morikawa A, Ito H, Sugiyama T, Hassan F, Islam S, et al. Defective responsiveness of CD5+ B1 cells to lipopolysaccharide in cytokine production. J Endotoxin Res. 2006;12:346-51 pubmed
    ..Defective responsiveness of TH2.52 B1 cells to LPS in cytokine production might be responsible for the failure of IFN-beta production due to the lack of molecules participating in the MyD88-independent pathway. ..
  28. Plaza J, Comfere N, Gibson L, Colgan M, Davis D, Pittelkow M, et al. Unusual cutaneous manifestations of B-cell chronic lymphocytic leukemia. J Am Acad Dermatol. 2009;60:772-80 pubmed publisher
    ..Additional investigations into the behavior of B-CLL in the skin may elucidate further the evolution of cutaneous lesions in this disease. ..
  29. Vera J, Fenutría R, Cañadas O, Figueras M, Mota R, Sarrias M, et al. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci U S A. 2009;106:1506-11 pubmed publisher
  30. Golardi N, Velasco M, Elghetany M. Marginal zone variant of mantle cell lymphoma: CD5-negative cyclin D1-positive variant posing a diagnostic dilemma. Pathol Int. 2009;59:317-21 pubmed publisher
    ..Differentiating MCL from MZL has prognostic and therapeutic implications, particularly when considering the potential role of targeted therapy and cell cycle modulators. ..
  31. Gujral S, Agarwal A, Gota V, Nair R, Gupta S, Pai S, et al. A clinicopathologic study of mantle cell lymphoma in a single center study in India. Indian J Pathol Microbiol. 2008;51:315-22 pubmed
    ..Bone marrow was involved in 25 (59%) cases. Thirty-two patients could be treated. Median recurrence-free survival was 22.23 months. Diffuse pattern of nodal involvement had a lower overall survival. ..
  32. Saini M, Sinclair C, Marshall D, Tolaini M, Sakaguchi S, Seddon B. Regulation of Zap70 expression during thymocyte development enables temporal separation of CD4 and CD8 repertoire selection at different signaling thresholds. Sci Signal. 2010;3:ra23 pubmed publisher
  33. Tagawa H. [Detection for subtype-specific genomic/genetic alterations in diffuse large B-cell lymphoma (DLBCL)]. Rinsho Ketsueki. 2008;49:73-81 pubmed
  34. Sayala H, Rawstron A, Hillmen P. Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2007;20:499-512 pubmed
    ..In this chapter we briefly review the existing methods for MRD assessment, the clinical relevance of MRD eradication in CLL, and the therapies available to attain this endpoint. ..
  35. de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25:805-12 pubmed
    ..Harmonization of techniques and centralized consensus review appears mandatory when using immunohistochemical biomarkers for treatment stratification. ..
  36. Rossmann E, Lundin J, Lenkei R, Mellstedt H, Osterborg A. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J. 2001;2:300-6 pubmed
    ..Caution must be taken when interpreting in vitro results on cytokine-mediated receptor intensity up-regulation. ..
  37. Karnan S, Tagawa H, Suzuki R, Suguro M, Yamaguchi M, Okamoto M, et al. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization. Genes Chromosomes Cancer. 2004;39:77-81 pubmed
    ..This indicates that CD5+ DLBCL constitutes a disease category distinct from that of CD5- DLBCL and other CD5+ malignancies. ..
  38. Karandikar N, Kroft S, Yegappan S, Rogers B, Aquino V, Lee K, et al. Unusual immunophenotype of CD8+ T cells in familial hemophagocytic lymphohistiocytosis. Blood. 2004;104:2007-9 pubmed
    ..This case provides an instructive example of uncontrolled reactive proliferation of CD8+ T cells in FHL, resulting in atypical morphology and unusual immunophenotypic features that might suggest malignancy in other clinical settings. ..
  39. Yuling H, Ruijing X, Xiang J, Yanping J, Lang C, Li L, et al. CD19+CD5+ B cells in primary IgA nephropathy. J Am Soc Nephrol. 2008;19:2130-9 pubmed publisher
    ..In conclusion, these results strongly suggest that CD19(+)CD5(+) B cells play a prominent role in the pathogenesis of primary IgA nephropathy. ..
  40. Inaba T, Shimazaki C, Sumikuma T, Nakagawa M. T-cell associated antigen-positive B-cell lymphoma. Leuk Lymphoma. 2001;42:1161-71 pubmed
    ..In addition, two-color FCM for detecting such aberrant T-Ag expression in B-NHL is useful for monitoring the minimal residual disease in the subgroup with T-Ag(+) B-NHL. ..
  41. Aguado E, Richelme S, Nunez Cruz S, Miazek A, Mura A, Richelme M, et al. Induction of T helper type 2 immunity by a point mutation in the LAT adaptor. Science. 2002;296:2036-40 pubmed
    ..This paradoxical phenotype establishes an unanticipated inhibitory function for LAT that is critical for the differentiation and homeostasis of TH cells. ..
  42. Ulivieri C, Valensin S, Majolini M, Matthews R, Baldari C. Normal B-1 cell development but defective BCR signaling in Lck-/- mice. Eur J Immunol. 2003;33:441-5 pubmed
    ..The data suggest a potential role for Lck in the achievement of the higher activation threshold required for productive BCR signaling in B-1 as compared to B-2 cells. ..
  43. Veneri D, Franchini M, de Sabata D, Ledro S, Vella A, Ortolani R, et al. Peripheral blood CD5-positive B lymphocytes (B-1a cells) after allogeneic stem cell transplantation for acute myeloid leukaemia in humans. Blood Transfus. 2008;6:220-4 pubmed
    ..Further studies are necessary in order to clarify the origin of B-1a cells in humans in health and illness. ..
  44. Jin M, Liu B, Wang L, Xu J. [Clinicopathologic study of metaplastic thymoma]. Zhonghua Bing Li Xue Za Zhi. 2006;35:285-8 pubmed
    ..They were not detected within the spindle cells. Metaplastic thymoma is a rarely encountered indolent or low-grade thymic tumor and may represent a distinct clinicopathologic entity. ..
  45. Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008;19:1921-6 pubmed publisher
    ..Further studies with larger numbers are warranted to confirm the prognostic significance of CD5 expression for patients with DLBCL receiving rituximab-containing chemotherapy. ..
  46. Pajor L, Lacza A, Kereskai L, Jáksó P, Egyed M, Iványi J, et al. Increased incidence of monoclonal B-cell infiltrate in chronic myeloproliferative disorders. Mod Pathol. 2004;17:1521-30 pubmed
    ..Modern Pathology (2004) 17, 1521-1530, advance online publication, 16 July 2004; doi:10.1038/modpathol.3800225. ..
  47. Ek S, Dictor M, Jerkeman M, Jirstrom K, Borrebaeck C. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood. 2008;111:800-5 pubmed
  48. Tagawa H, Tsuzuki S, Suzuki R, Karnan S, Ota A, Kameoka Y, et al. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases. Cancer Res. 2004;64:5948-55 pubmed
    ..These results suggest that array-based comparative genomic hybridization analysis provides a platform of genomic aberrations of DLBCL both common and specific to clinically distinct subgroups. ..
  49. Lai S, Lin J, Lai S, Wu Y. Influence of Ganoderma lucidum on blood biochemistry and immunocompetence in horses. Am J Chin Med. 2004;32:931-40 pubmed
    ..001). Experimental result on humoral immunity showed that G. lucidum could help the horses to produce a significantly higher quantity of specific antibodies in a shorter time (p < 0.001). ..
  50. Marti G, Rawstron A, Ghia P, Hillmen P, Houlston R, Kay N, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130:325-32 pubmed
    ..Future studies of MBL should be directed towards determining its relationship to clinical disease, particularly in individuals from families with a genetic predisposition to developing CLL. ..
  51. Suguro M, Tagawa H, Kagami Y, Okamoto M, Ohshima K, Shiku H, et al. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci. 2006;97:868-74 pubmed
  52. Nguyen L, Ramanathan M, Weinstock Guttman B, Baier M, Brownscheidle C, Jacobs L. Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci. 2003;209:93-9 pubmed
    ..49, P=0.018). The secretion of the pro-inflammatory cytokines, IFN-gamma and TNF-alpha, is influenced by gender in MS patients and may contribute to the sexual dimorphism of MS. ..
  53. Barr P, Lazarus H, Cooper B, Schluchter M, Panneerselvam A, Jacobberger J, et al. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am J Hematol. 2009;84:484-7 pubmed publisher
    ..Future investigations of agents targeting the protein kinase C pathway may benefit from early response assessment using flow cytometry to evaluate T-cell apoptosis. ..